Alzheimer's disease dementia with psychosis/agitation/aggression
Mental health · 2015–2015
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| risperidone Amendment to current restriction for treatment of dementia to align with TGA-approved changes, limiting use to moderate to severe dementia of the Alzheimer's… | Nov 2015 | Recommended | input received |
What the PBS pays
$21M in government benefit over 2024–25, across 498,065 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| risperidone | $21.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.